CN117379361A - Formula for treating gout and preparation method thereof - Google Patents
Formula for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN117379361A CN117379361A CN202311561280.9A CN202311561280A CN117379361A CN 117379361 A CN117379361 A CN 117379361A CN 202311561280 A CN202311561280 A CN 202311561280A CN 117379361 A CN117379361 A CN 117379361A
- Authority
- CN
- China
- Prior art keywords
- raw materials
- tea
- juice
- beverage
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 244000269722 Thea sinensis Species 0.000 claims abstract description 46
- 239000002994 raw material Substances 0.000 claims abstract description 42
- 235000013361 beverage Nutrition 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 37
- 235000013616 tea Nutrition 0.000 claims abstract description 32
- 239000007787 solid Substances 0.000 claims abstract description 24
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 21
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 20
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 18
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 18
- 235000004936 Bromus mango Nutrition 0.000 claims abstract description 16
- 235000014826 Mangifera indica Nutrition 0.000 claims abstract description 16
- 235000009184 Spondias indica Nutrition 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000011332 Brassica juncea Nutrition 0.000 claims abstract description 14
- 244000178993 Brassica juncea Species 0.000 claims abstract description 14
- 235000014700 Brassica juncea var napiformis Nutrition 0.000 claims abstract description 14
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 14
- 244000242564 Osmanthus fragrans Species 0.000 claims abstract description 14
- 235000019083 Osmanthus fragrans Nutrition 0.000 claims abstract description 14
- 241001523681 Dendrobium Species 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 12
- 240000007228 Mangifera indica Species 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 36
- 241000219173 Carica Species 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 claims description 13
- 235000009569 green tea Nutrition 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 235000010678 Paulownia tomentosa Nutrition 0.000 claims description 6
- 240000002834 Paulownia tomentosa Species 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000007670 refining Methods 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 240000000425 Chaenomeles speciosa Species 0.000 claims description 4
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims description 4
- 240000004638 Dendrobium nobile Species 0.000 claims description 4
- XSBJUSIOTXTIPN-UHFFFAOYSA-N aluminum platinum Chemical compound [Al].[Pt] XSBJUSIOTXTIPN-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 241001076416 Dendrobium tosaense Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 6
- 241001299699 Idesia Species 0.000 claims 1
- 241000219295 Portulaca Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 24
- 230000036407 pain Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 231100000957 no side effect Toxicity 0.000 abstract description 6
- 208000005298 acute pain Diseases 0.000 abstract description 5
- 238000010791 quenching Methods 0.000 abstract description 5
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 240000006432 Carica papaya Species 0.000 abstract 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 29
- 230000000694 effects Effects 0.000 description 21
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 19
- 229940116269 uric acid Drugs 0.000 description 19
- 241000219304 Portulacaceae Species 0.000 description 13
- 239000008280 blood Substances 0.000 description 10
- 241001093152 Mangifera Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000026010 Dendrobium candidum Species 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241001678082 Dendrobium huoshanense Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- -1 bromarone Chemical compound 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MLFIYYDKLNZLAO-UHFFFAOYSA-N 2-aminoethane-1,1-diol Chemical compound NCC(O)O MLFIYYDKLNZLAO-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000244987 Daiswa polyphylla Species 0.000 description 1
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The embodiment of the invention discloses a formula for treating gout, which comprises the following raw materials of papaya, dendrobium, ganoderma lucidum spore powder, purslane, platycodon grandiflorum, mango, tea, sweet osmanthus, and brassica juncea; wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea; the drink for relieving pains of patients with gout is displayed in a liquid or solid state, is fully proportioned, steamed at high temperature, is nontoxic and sterile, fully exerts medicine property and is very easy to be absorbed by human bodies; the user does not need to take the tea with water again, and the tea is convenient and quick to drink; the raw materials are food-grade medicinal materials, so that the food can be drunk for a long time as a thirst-quenching beverage in daily life, and can prevent acute pain caused by gout; and the preparation method is safe, has no side effect and has reasonable manufacturing cost.
Description
Technical Field
The invention relates to the technical field of auxiliary treatment of gout, in particular to a formula for treating gout and a preparation method thereof.
Background
Gout is a recurrent inflammatory disease caused by increased purine biosynthesis and metabolism, excessive uric acid production or elevated uric acid in blood due to poor uric acid excretion, and deposition of urate crystals in joint synovium, bursa, cartilage and other tissues. The clinical characteristics are as follows: hyperuricemia and urate crystallization, characteristic acute arthritis, tophus and interstitial nephritis caused by deposition, joint deformity and dysfunction are seen in serious cases, uric acid urinary tract stones are often found in middle-aged and elderly men with obesity and post-menopausal women, and the prevalence rate of the uric acid urinary tract stones is gradually increased along with economic development and life style changes.
For some gout patients, the direct pathological mechanism of hyperuricemia is reduced clearance of the renal tubules to the uric acid salts. Renal excretion of urate is by glomerular filtration, but filtered urate is almost completely absorbed by proximal tubules (pre-secretion reabsorption), and the urate moiety secreted by the tubules is reabsorbed at the distal ends of proximal tubules, and a small amount is reabsorbed at henry loops and collecting vessels (post-secretion reabsorption). Thus, urate excretion is almost that secreted by the tubular ducts, and final uric acid excretion from the kidneys is 6% -12% of glomerular filtration. Reduced renal excretion of urate can result in hyperuricemia when glomerular urate filtration is reduced, reabsorption of urate by the tubules is increased, or renal tubules excrete urate is reduced.
The basic methods for treating gout at present are three: 1. autumn water new alkali medicine: such as febuxostat, bromarone, allopurinol and the like; 2. hormonal drugs; 3. antiphlogistic and analgesic medicines; however, the treatment method can treat the symptoms, not the root cause, can not prevent the progress of gout, and has large and more side effects.
At present, a plurality of products for treating gout are available on the market, but few beverages special for rapidly relieving pains of patients with gout can rapidly relieve pains of patients with gout in the drinking process. At present, the products for treating gout are solid or highly concentrated products in the market, or are taken by drinking water, or a proper amount of drinking water is needed after taking, so that the absorption is enhanced, and the products are extremely inconvenient for patients. Therefore, the beverage provided by the application can quickly relieve pain caused by gout attack, has a certain effect of treating gout, and is convenient for all gout patients to drink.
Disclosure of Invention
According to the formula and the preparation method for treating gout, the beverage for relieving pains of patients with gout is prepared in a liquid or solid mode, is prepared fully, is steamed at high temperature, is nontoxic and sterile, has full play of drug properties, and is easy to be absorbed by human bodies; the user does not need to take the tea with water again, and the tea is convenient and quick to drink; the raw materials are food-grade medicinal materials, so that the food can be drunk for a long time as a thirst-quenching beverage in daily life, and can prevent acute pain caused by gout; and the preparation method is safe, has no side effect and has reasonable manufacturing cost.
The embodiment of the application provides a formula for treating gout, which comprises the following raw materials,
papaya, dendrobium, ganoderma lucidum spore powder, purslane, platycodon grandiflorum, mango, tea, osmanthus fragrans and brassica juncea;
wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea.
Further, the papaya is chaenomeles speciosa nakai.
Further, the dendrobium is dendrobium huoshanense.
Further, the purslane is purslane with big leaves in the origin of the tung city of Anhui.
Further, the platycodon grandiflorum is a platycodon grandiflorum in a producing area of the tung city of Anhui.
Further the tea leaves are green tea or Tieguanyin tea; the green tea is selected from small flower green tea of Anhui tung city.
Further a preparation method of a liquid plant beverage for treating gout, which specifically comprises the following steps,
(1) Juice preparation: the preparation method comprises the steps of preparing according to the formula, wherein the total weight is 200KG, wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium nobile, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea, and adding the prepared raw materials and 1000KG of water into a steam furnace for boiling to form juice;
(2) Filtering juice: leading out the juice formed in the step (1) from a steam oven, filtering by adopting a fine filter screen, and precipitating fine residues contained in the juice to the bottom of a container by utilizing ultrasonic vibration to carry out deslagging treatment to obtain purified juice;
(3) Juice storage: placing the purified juice in the step (2) in an environment of 25 ℃ for storage for later use;
(4) Preparing a beverage: adding 0.5-1% of honey into the juice prepared in the step (3), and uniformly stirring by using a homogenizer to obtain beverage juice;
(5) Packaging the beverage juice: packaging the beverage juice prepared in the step (4) into metal cans, sterilizing at 116-124 ℃, filling and sealing by pipeline machine operation to obtain the finished beverage.
Further, the temperature in the steam furnace in the step (1) is 100-130 ℃, and water and raw materials are boiled for 2 hours.
Further a preparation method of the solid plant beverage for treating gout comprises the following steps,
(1) The raw materials are as follows: preparing materials according to a formula, wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea;
(2) Drying raw materials: the raw materials prepared in the step (1) are respectively and separately dried, the baking temperature is 50-80 ℃, and the drying is stopped until the water content of the raw materials is lower than 7%, so that the dried raw materials are obtained for standby;
(3) Grinding: uniformly mixing the dried raw materials in the step (2), and coarsely grinding into powder particles of 200-300 meshes to obtain coarse solid powder;
(4) Fine treatment: refining the crude solid powder obtained in the step (3) in a deep low-temperature environment, and refining the powder particles to 50-100nm to obtain fine solid powder;
(5) Powder packaging: and (3) carrying out aluminum-platinum split charging on the fine solid powder obtained in the step (4) to obtain a finished plant solid beverage.
Further, the deep low temperature ambient temperature of the fine grinding treatment in the above (4) is from-60 ℃ to-198 ℃.
One or more technical solutions provided in the embodiments of the present application at least have the following technical effects or advantages: the drink for relieving pains of patients with gout is displayed in a liquid or solid state, is fully proportioned, steamed at high temperature, is nontoxic and sterile, fully exerts medicine property and is very easy to be absorbed by human bodies; the user does not need to take the tea with water again, and the tea is convenient and quick to drink; the raw materials are food-grade medicinal materials, so that the food can be drunk for a long time as a thirst-quenching beverage in daily life, and can prevent acute pain caused by gout; the preparation method is safe, has no side effect and has reasonable manufacturing cost; the effective components of the medicinal materials for treating gout are fully extracted, and the medicinal materials are prepared by a compound extraction process to prepare the beverage, so that the components are most easily and rapidly absorbed by human bodies, and the pain of patients caused by gout can be relieved more rapidly.
Detailed Description
The present invention will be described more fully hereinafter in order to facilitate an understanding of the present invention. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
Example 1
A prescription for treating gout comprises the following raw materials,
papaya, dendrobium, ganoderma lucidum spore powder, purslane, platycodon grandiflorum, mango, tea, osmanthus fragrans and brassica juncea;
wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea.
Papaya is preferably chaenomeles speciosa. The fresh papaya fruits contain more tannins and organic acids, and the sugar content is relatively low, but the fruits are rich in nutrition and vitamins; simultaneously, the papaya also has the efficacy of health care and diet therapy, and the protease contained in the papaya can compensate secretion of pancreas and intestinal tracts, supplement deficiency of gastric juice and is beneficial to decomposing protein and starch. The papaya contains carotene and rich vitamin C, has strong antioxidation capability, helps organism repair tissues, eliminates toxic substances, enhances human immunity, and helps organism resist virus attack;
wherein, the chaenomeles speciosa contains 19 amino acids, 18 mineral microelements, a large amount of vitamin C and the like, has extremely high medicinal value, has the effects of calming liver and harmonizing stomach, dispelling wind and removing dampness, promoting blood circulation and removing obstruction in collaterals, nourishing spleen and tonifying lung and the like, is mainly used for treating symptoms such as rheumatism paralysis, beriberi gall, bacillary dysentery, cholera, vomiting and diarrhea, gastrocnemius muscle spasm and the like, and is known as plant gold.
The herba Dendrobii is preferably Dendrobium officinale Kimura et Migo. The dendrobium has long history of medicinal use, is rich and balanced in medicinal components, can treat various diseases, and is clinically used for treating or assisting treatment of chronic pharyngitis, gastrointestinal diseases, ophthalmic diseases, thrombotic occlusive diseases, diabetes, arthritis and cancers. The herba Dendrobii can be administered by fresh herba Dendrobii and dried herba Dendrobii; fresh Dendrobium nobile is indicated for patients with heat and dysphoria with high fever because it has strong heat clearing and fluid generating effects and pathogenic heat entering nutrient blood; the dried dendrobium candidum has the effects of nourishing yin and clearing and tonifying for a long time, and is suitable for patients with yin deficiency and deficiency heat in the later stage of heat disease;
the dendrobium candidum is also called dendrobium candidum, is a best quality in dendrobium candidum, and the dendrobium candidum produced in Huoshan county of Anhui province is a best quality in dendrobium candidum. Dendrobium huoshanense is rich in more than ten alkaloids such as polysaccharide, amino acid, dendrobine and the like. Is identified by medical plant research institute of Chinese medical science academy: the polysaccharide content is 18.974% and the total alkaloid content is 0.030%. Can effectively improve the immunity of organisms, has special curative effects on organs such as eyes, pharynx, lung, stomach, intestines, kidneys, blood, cardiovascular diseases and the like of human bodies, and can resist cataract, delay senility, resist mutation and resist tumors.
The Ganoderma spore powder has all genetic materials of Ganoderma and health promoting effects, and can enhance immunity, inhibit tumor, protect liver injury, and protect against radiation.
The herba Portulacae is preferably herba Portulacae of Paris polyphylla in Anhui province. Purslane contains rich nutrients such as dihydroxyethylamine, malic acid, glucose, calcium, phosphorus, iron, vitamin E, carotene, vitamin B, vitamin C and the like. Purslane has a prominent characteristic in nutrition, and the omega-3 fatty acid content of purslane is higher than that of human and plants. Omega-3 fatty acid can inhibit the absorption of cholesterol by human body, reduce the concentration of cholesterol in blood, improve the elasticity of blood vessel wall and is very beneficial to preventing and treating cardiovascular diseases.
The radix Platycodi is preferably radix Platycodi in Anhui city. Radix Platycodi is dry root of radix Platycodi of Campanulaceae, has bitter and pungent taste, and has effects of dispersing lung qi, relieving sore throat, eliminating phlegm, expelling pus, and relieving inflammation.
Mango contains a large amount of myo-inositol, choline and vitamin E, and the three substances act together, so that a large amount of hypoxanthine and xanthine can be chelated, and the mango is discharged out of the body along with urine, so that uric acid generation is reduced, and cholesterol is reduced; helping redistribution and redistribution of fat in the body; and tranquilizing and analgesic effects.
The tea is preferably Anhui tung city small flower green tea or Tieguanyin tea. The tea contains more than four hundred fifty organic chemical components and more than forty inorganic mineral elements. Tea polyphenol contained in the tea has strong oxidation resistance and physiological activity, is a scavenger of human free radicals, can block the synthesis of various cancerogenic substances such as nitrous acid amine in vivo, and can absorb radioactive substances to achieve the effect of radiation protection;
wherein the green tea is unfermented and is characterized by clear green leaves. The green tea has the pharmacological effects of refreshing, clearing heart fire, clearing summer heat, promoting digestion, resolving phlegm, removing greasiness, losing weight, clearing heart fire, relieving restlessness, detoxifying, sobering up, promoting fluid production, quenching thirst, reducing fire, improving eyesight, stopping diarrhea, removing dampness and the like, and has certain pharmacological effects on modern diseases such as radiation diseases, cardiovascular and cerebrovascular diseases, cancers and the like;
tieguanyin tea belongs to green tea, is between green tea and black tea, belongs to semi-fermented tea, has the health-care functions of common tea, and also has the effects of resisting aging, resisting arteriosclerosis, preventing and treating diabetes, losing weight and building body, preventing and treating dental caries, clearing heat and reducing fire, dispelling smoke and sobering up and the like. Tieguanyin contains high amino acids, vitamins, minerals, tea polyphenols and alkaloids, and has various nutritional and medicinal effects. .
Semen Sinapis Albae is a common Chinese medicinal material with mild nature and pungent taste. Has effects of moistening lung, resolving phlegm, relieving swelling and pain, warming spleen and stomach, dispelling cold, promoting diuresis, removing blood stasis, dredging channels and collaterals, and relieving swelling and toxin, and can be used for treating gastric cold emesis, heart and abdominal pain, cough due to lung cold, arthromyodynia, pharyngitis, phlegm, traumatic injury, etc.
Example two
A preparation method of a liquid plant beverage for treating gout comprises the following steps:
(1) Juice preparation: the preparation method comprises the steps of preparing according to the formula, wherein the total weight is 200KG, wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium nobile, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea, and adding the prepared raw materials and 1000KG of water into a steam furnace for boiling to form juice;
(2) Filtering juice: leading out the juice formed in the step (1) from a steam oven, filtering by adopting a fine filter screen, and precipitating fine residues contained in the juice to the bottom of a container by utilizing ultrasonic vibration to carry out deslagging treatment to obtain purified juice;
(3) Juice storage: placing the purified juice in the step (2) in an environment of 25 ℃ for storage for later use;
(4) Preparing a beverage: adding 0.5-1% of honey into the juice prepared in the step (3), and uniformly stirring by using a homogenizer to obtain beverage juice;
(5) Packaging the beverage juice: packaging the beverage juice prepared in the step (4) into metal cans, sterilizing at 116-124 ℃, filling and sealing by pipeline machine operation to obtain the finished beverage.
The temperature in the steam furnace in the step (1) is 100-130 ℃, and water and raw materials are boiled for 2 hours.
Honey is a natural food, which is composed of glucose and fructose of monosaccharides, and can be directly absorbed by human body without enzyme decomposition. The honey can be used for health care and longevity, and clinically, the honey can be used for treating gastritis and can be added with certain medicines for treating ulcer; meanwhile, the Chinese medicinal composition has a good protective effect on spleen and stomach, and also has the effect of relaxing bowel, and is especially suitable for the elderly with qi deficiency and constipation.
The technical scheme in the embodiment of the application at least has the following technical effects or advantages: the drink for relieving pains of patients with gout is displayed in a liquid state, is fully proportioned, steamed at high temperature, is nontoxic and sterile, fully exerts drug properties and is very easy to be absorbed by human bodies; the user does not need to take the tea with water again, and the tea is convenient and quick to drink; the raw materials are food-grade medicinal materials, so that the food can be drunk for a long time as a thirst-quenching beverage in daily life, and can prevent acute pain caused by gout; the preparation method is safe, has no side effect and has reasonable manufacturing cost; the effective components of the medicinal materials for treating gout are fully extracted, and the medicinal materials are prepared by a compound extraction process to prepare the beverage, so that the components are most easily and rapidly absorbed by human bodies, and the pain of patients caused by gout can be relieved more rapidly.
Example III
The preparation method of the solid plant beverage for treating gout comprises the following steps:
(1) The raw materials are as follows: preparing materials according to a formula, wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea;
(2) Drying raw materials: drying the prepared raw materials in the step (1) respectively until the water content of the raw materials is lower than 7%, and stopping drying to obtain dried raw materials for later use;
(3) Grinding: uniformly mixing the dried raw materials in the step (2), and coarsely grinding into powder particles of 200-300 meshes to obtain coarse solid powder;
(4) Fine treatment: refining the crude solid powder obtained in the step (3) in a deep low-temperature environment, and refining the powder particles to 50-100nm to obtain fine solid powder;
(5) Powder packaging: and (3) carrying out aluminum-platinum split charging on the fine solid powder obtained in the step (4) to obtain a finished plant solid beverage.
The baking temperature in the baking treatment in the step (2) is 50-80 ℃.
The deep low temperature ambient temperature of the fine grinding treatment in the above (4) is from-60 ℃ to-198 ℃.
The technical scheme in the embodiment of the application at least has the following technical effects or advantages: the drink for relieving pains of patients with gout is displayed in a solid powder form, and can be taken by patients in later period by water. The solid plant drink has the advantages of realizing the effects of rapidly relieving pains caused by gout attack, simultaneously treating gout diseases and reducing uric acid in blood of human bodies, along with safety, no side effect, reasonable manufacturing cost and wide popularization to all gout patients.
Experimental data 1
Four years of data from a batch of testers demonstrated:
the cure rate of hyperuricemia and gout and mild hyperuricemia and gout is more than 70%;
in the patients with early and middle period gout in the testers, the relapse rate in two years is more than 50%;
the tester showed in the test: after 1 hour, uric acid concentrations were significantly reduced in more than 60% of the subjects; after 3 days, uric acid concentrations were significantly reduced in more than 70% of the subjects; uric acid concentrations were significantly reduced in greater than 80% of the subjects during the period of 1 week to 1 month; in 1 course of treatment, uric acid concentration of more than 90% of testers is obviously reduced, and the trend of reducing uric acid concentration is rapid and stable without other auxiliary treatment;
the pain of the testers is relieved within 1-2 hours, the pain is basically eliminated in about one day, and hormone and pain relieving tablets are not required to be taken;
after the formula is used by gout patients in testers, the blood uric acid concentration is continuously stabilized for more than 3 months, the use can be stopped, reasonable diet and proper exercise are matched during the trial period, and more than 70% of gout patients have no recurrence for two years.
Experimental data two
Through 1200 clinical observations over four years, the effect is described as follows:
1. the instant effect is as follows: more than 70% of patients are compared before and after taking by using a Baijieyu uric acid tester, and uric acid is obviously reduced after 40-60 minutes; when the pain is in an acute pain period, the pain can be relieved within 1-2 hours, the pain is basically disappeared after 24 hours under the premise of limiting the activities, the pain eliminating rate reaches 60-65%, and the swelling eliminating rate reaches 70%;
2. patients with gout (including hyperuricemia) at stage one to two have no recurrence rate of about 50% for 1-2 years after 1-5 treatment courses; patients in three to four stages have obviously reduced acute attack and obviously reduced attack degree; the five-stage patients (patients with liver and kidney function injury, gouty diabetes, gouty hypertension and gouty heart) have longer curative effect and longer effective time, but have better curative effect compared with the traditional various medicines for treating the gouty disease.
3. No side effect is found on human body at present, and the food is used as food, the dosage is small, and the human body is not damaged.
4. The medicine has obvious stone eliminating effect on patients with tophus in joints after long-term administration, and some patients can completely eliminate the stones.
Experimental data three
The concentration of the blood uric acid of the patient is reduced from 690 mu mol/L to 480 mu mol/L after 60 minutes after the patient takes the beverage prepared by the formula;
the concentration of the di-blood uric acid of the patient is reduced from 480 mu mol/L to 450 mu mol/L after 45 minutes after the patient takes the beverage prepared by the formula;
patient three takes the beverage prepared by the formula, and after 60 minutes, the concentration of the patient three blood uric acid is reduced from 582 mu mol/L to 540 mu mol/L;
the concentration of the tetrauric acid of the patient is reduced from 702 mu mol/L to 614 mu mol/L after 55 minutes after the patient takes the beverage prepared by the formula;
after the patient takes the beverage prepared by the formula for 7 days, the concentration of penta-haematuria acid of the patient is reduced from 611 mu mol/L to 412 mu mol/L;
six patients took the beverage prepared by the formula, and after 30 days, the concentration of the hexaxuridine acid of the patients is reduced from 542 mu mol/L to 301 mu mol/L.
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A formula for treating gout, which is characterized in that: comprises the following raw materials,
papaya, dendrobium, ganoderma lucidum spore powder, purslane, platycodon grandiflorum, mango, tea, osmanthus fragrans and brassica juncea;
wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea.
2. A formulation for treating gout according to claim 1, wherein: the papaya is chaenomeles speciosa nakai.
3. A formulation for treating gout according to claim 1, wherein: the herba Dendrobii is Dendrobium officinale Kimura et Migo.
4. A formulation for treating gout according to claim 1, wherein: the purslane is Portulaca grandifolia in the origin of Anhui tung city.
5. The formula and the preparation method for treating gout according to claim 1, wherein the formula is characterized in that: the platycodon grandiflorum is a platycodon grandiflorum in a producing area of an idesia city.
6. The formula and the preparation method for treating gout according to claim 1, wherein the formula is characterized in that: the tea is green tea or Tieguanyin tea; the green tea is selected from small flower green tea of Anhui tung city.
7. A formulation for treating gout according to claim 1, wherein: the preparation method of the liquid plant beverage specifically comprises the following steps,
(1) Juice preparation: the preparation method comprises the steps of preparing according to the formula, wherein the total weight is 200KG, wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium nobile, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea, and adding the prepared raw materials and 1000KG of water into a steam furnace for boiling to form juice;
(2) Filtering juice: leading out the juice formed in the step (1) from a steam oven, filtering by adopting a fine filter screen, and precipitating fine residues contained in the juice to the bottom of a container by utilizing ultrasonic vibration to carry out deslagging treatment to obtain purified juice;
(3) Juice storage: placing the purified juice in the step (2) in an environment of 25 ℃ for storage for later use;
(4) Preparing a beverage: adding 0.5-1% of honey into the juice prepared in the step (3), and uniformly stirring by using a homogenizer to obtain beverage juice;
(5) Packaging the beverage juice: packaging the beverage juice prepared in the step (4) into metal cans, sterilizing at 116-124 ℃, filling and sealing by pipeline machine operation to obtain the finished beverage.
8. A formulation for treating gout according to claim 7, wherein: the temperature in the steam furnace in the step (1) is 100-130 ℃, and water and raw materials are boiled for 2 hours.
9. A formulation for treating gout according to claim 1, wherein: the preparation method of the solid plant beverage specifically comprises the following steps,
(1) The raw materials are as follows: preparing materials according to a formula, wherein the raw materials comprise 60-80% of papaya, 9.5-38% of dendrobium, 9.8-18% of ganoderma lucidum spore powder, 1.5-3.8% of purslane, 0.5-2% of platycodon grandiflorum, 0.2-20% of mango, 0.8-1.8% of tea, 0.5-1% of sweet osmanthus and 0.5-1% of brassica juncea;
(2) Drying raw materials: the raw materials prepared in the step (1) are respectively and separately dried, the baking temperature is 50-80 ℃, and the drying is stopped until the water content of the raw materials is lower than 7%, so that the dried raw materials are obtained for standby;
(3) Grinding: uniformly mixing the dried raw materials in the step (2), and coarsely grinding into powder particles of 200-300 meshes to obtain coarse solid powder;
(4) Fine treatment: refining the crude solid powder obtained in the step (3) in a deep low-temperature environment, and refining the powder particles to 50-100nm to obtain fine solid powder;
(5) Powder packaging: and (3) carrying out aluminum-platinum split charging on the fine solid powder obtained in the step (4) to obtain a finished plant solid beverage.
10. The formula and the preparation method for treating gout according to claim 9, wherein: the deep low temperature ambient temperature of the fine grinding treatment in the above (4) is-60 ℃ to-198 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311561280.9A CN117379361A (en) | 2023-11-22 | 2023-11-22 | Formula for treating gout and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311561280.9A CN117379361A (en) | 2023-11-22 | 2023-11-22 | Formula for treating gout and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117379361A true CN117379361A (en) | 2024-01-12 |
Family
ID=89435817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311561280.9A Withdrawn CN117379361A (en) | 2023-11-22 | 2023-11-22 | Formula for treating gout and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117379361A (en) |
-
2023
- 2023-11-22 CN CN202311561280.9A patent/CN117379361A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108391774A (en) | A kind of drinks of antigout and preparation method thereof | |
CN110755542A (en) | Formula of uric acid-reducing gout-treating tea and preparation method thereof | |
CN101698061B (en) | Chinese medicinal liquor for nourishing yin and strengthening yang | |
CN102715613A (en) | Health-care beverage containing bamboo parasitic fungus and manufacture method thereof | |
CN117379361A (en) | Formula for treating gout and preparation method thereof | |
CN112690382A (en) | Beverage capable of clearing away heat and toxic materials | |
CN112294925A (en) | A medicine for treating gout, gastropathy and constipation, and its preparation method | |
CN104623424A (en) | Lactation promoting tea and preparation method thereof | |
CN105166174A (en) | Stomach-nourishing and saliva-increasing tea and processing method thereof | |
CN104651201A (en) | Vinegar for treating high blood pressure | |
CN104818177B (en) | One kind shield stomach kidney-tonifying life-prolonging wine and preparation method thereof | |
NL2030406B1 (en) | Composite honey paste for dispelling effects of alcohol and preparation method thereof | |
CN102224894B (en) | Angelica health preserving wine and preparation method thereof | |
CN105832867A (en) | Soaking method of pepper and centipede selenium-rich medicinal liquor | |
CN106107286A (en) | A kind of Chinese herbal medicine Radix Notoginseng beverage and preparation method thereof | |
CN105832868A (en) | Soaking method of pepper and cantharides selenium-rich medicinal liquor | |
CN105288095A (en) | Traditional Chinese medicinal composition for treating diabetes, and preparation method thereof | |
CN112210465A (en) | Anise vinegar and brewing process thereof | |
CN113841766A (en) | Compound jujube needle tea with hypertension preventing and treating effect | |
CN112772908A (en) | Preparation method of tea polyphenol-rich medicinal and edible plant enzyme | |
KR20030026942A (en) | Anti-atopic Health Assistance Tea | |
CN112933180A (en) | Spray for regulating diabetes and preparation method thereof | |
CN116077599A (en) | Shennong kudzuvine acid tea formula and preparation method thereof | |
CN111450202A (en) | A Chinese medicinal composition for preventing and treating hypertension, hyperglycemia and hyperlipidemia, and its preparation method | |
CN114009771A (en) | Formula and preparation method of gout food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20240112 |